Abstract:Background: Proline-rich transmembrane protein 2 (PRRT2) plays an important role in the central nervous system and mutations in the gene are implicated in a variety of neurological disorders. This study aimed to summarize the clinical characteristics and gene expression analysis of neurological diseases related to the PRRT2 gene and explore the clinical characteristics, therapeutic effects, and possible pathogenic mechanisms of related diseases. Methods: We enrolled 10 children with PRRT2 mutation-related neurological diseases who visited the Children's Hospital affiliated with the Shanghai Jiaotong University School of Medicine/Shanghai Children's Hospital between May 2017 and February 2022. Video electroencephalography (VEEG), cranial imaging, treatment regimens, gene results, and gene expression were analyzed. Genetic testing involved targeted sequencing or whole-exome genome sequencing (WES). We further analyzed the expression and mutation conservation of PRRT2 and synaptosome-associated protein 25 (SNAP25) in blood samples using quantitative polymerase chain reaction (qPCR) and predicted the protein structure. Summary analysis of the reported gene maps and domains was also performed. Results: Ten children with PRRT2 gene mutations were analyzed, and 4 mutations were identified, consisting of 2 new (c.518A > C, p.Glu173 Ala; c.879 + 112G > A, p.?) and two known (c. 649 dup, p. Arg217Profs * 8; c. 649 del, p. Arg217Glufs * 12) mutations. Among these mutations, one was de novo (P6), and three could not be determined because one parent refused genetic testing. The clinical phenotypes were paroxysmal kinesigenic dyskinesia (PKD), benign familial infantile epilepsy (BFIE), epilepsy, infantile spasms, and intellectual disability. The qPCR results showed that PRRT2 gene expression levels were significantly lower in children and parent carriers than the control group. The SNAP25 gene expression level of affected children was significantly lower ( P ≤ 0.001) than that of the control group. The mutation sites reported in this study are highly conserved in different species. Among the various drugs used, oxcarbazepine and sodium valproate were the most effective. All 10 children had a good disease prognosis, and 8 were completely controlled with no recurrence, whereas 2 had less severe and fewer seizures. Conclusion: Mutation of PRRT2 led to a significant decrease in its protein expression level and that of SNAP25, suggesting that the mutant protein may lead to the loss of its function and that of related proteins. This mutation site is highly conserved in most species, and there was no significant correlation between specific PRRT2 genotypes and clinical phenotypes. Asymptomatic carriers also have decreased gene expression levels, suggesting that more factors are involved.

Phenotypic and Genotypic Features of Twenty Children with Classic Pantothenate Kinase-Associated Neurodegeneration

Natural history and genotype-phenotype correlation of pantothenate kinase-associated neurodegeneration

Novel compound heterozygous mutations in the PANK2 gene in a Chinese patient with atypical pantothenate kinase-associated neurodegeneration.

Clinical characteristics of pantothenate kinase-associated neurodegeneration(report of 1 case)

Novel Compound Heterozygous of PARKIN Causes Early-Onset Parkinson's Disease

Novel PANK2 Mutations in Patients With Pantothenate Kinase-Associated Neurodegeneration and the Genotype–Phenotype Correlation

Novel PANK2 mutation in a Chinese boy with PANK2-associated neurodegeneration: A case report and review of Chinese cases.

[Clinical Features and PRRT2 Gene Mutation in Paroxysmal Kinesigenic Dyskinesia].

Patient and caregiver experiences with pantothenate kinase-associated neurodegeneration (PKAN): results from a patient community survey

PRRT2 mutations in a cohort of Chinese families with paroxysmal kinesigenic dyskinesia and genotype-phenotype correlation reanalysis in literatures.

[Clinical characteristics and molecular pathogenesis of pantothenate kinase-associated neurodegenerative disease].

PANK2 P.a170fs：a Novel Pathogenetic Mutation, Compound with PANK2 P.r440p, Causing Pantothenate Kinase Associated Neurodegeneration in a Chinese Family.

The first Vietnamese patient who presented late onset of pantothenate kinase-associated neurodegeneration diagnosed by whole exome sequencing: A case report

Clinical and genetic analysis of six families of paroxysmal kinesigenic dyskinesia

Clinical Phenotype Analysis of Paroxysmal Kinesigenic Dyskinesia

Clinical characteristics and genetics of ten Chinese children with PRRT2-associated neurological diseases

De novo KCNMA1 mutations in 3 children with paroxysmal nonkinesigenic dyskinesia and developmental delay

Case Report: Novel Compound Heterozygous Variants in the PANK2 Gene in a Chinese Patient Diagnosed with ASD and ADHD

[A phenotypic and genetic study on β-propeller protein-associated neurodegeneration].

Follow-Up Study of 25 Chinese Children with Pla2g6-Associated Neurodegeneration

Pilot trial on the efficacy and safety of pantethine in children with pantothenate kinase-associated neurodegeneration: a single-arm, open-label study